Company Description
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases.
Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
The company’s clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria.
It has a cooperative research and development agreement with National Institutes of Health’s National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome.
The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020.
Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 380 |
| CEO | Eric Dube |
Contact Details
Address: 3611 Valley Centre Drive, Suite 300 San Diego, California 92130 United States | |
| Phone | 888 969 7879 |
| Website | travere.com |
Stock Details
| Ticker Symbol | TVTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001438533 |
| CUSIP Number | 89422G107 |
| ISIN Number | US89422G1076 |
| Employer ID | 26-2383102 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Eric M. Dube Ph.D. | President, Chief Executive Officer and Director |
| Christopher Cline C.F.A. | Chief Financial Officer |
| Elizabeth E. Reed J.D. | Senior Vice President, General Counsel and Corporate Secretary |
| Dr. William E. Rote Ph.D. | Senior Vice President and Head of Research and Development |
| Peter Heerma | Chief Commercial Officer |
| Sandra Calvin | SVice President, Corporate Controller and Chief Accounting Officer |
| Nivi Nehra | Vice President of Corporate Communications and Investor Relations |
| Angela Giannantonio | Senior Vice President of Human Resources |
| Casey Logan | Chief Business Officer |
| Dr. Jula Inrig M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 4, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 31, 2024 | 424B5 | Filing |
| Oct 31, 2024 | 10-Q | Quarterly Report |
| Oct 31, 2024 | 8-K | Current Report |
| Oct 18, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 4, 2024 | 144 | Filing |
| Sep 30, 2024 | 144 | Filing |
| Sep 26, 2024 | 8-K | Current Report |
| Sep 11, 2024 | 144 | Filing |
| Sep 9, 2024 | 144 | Filing |